MedTrace Logo

Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion

NCT05787678 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-10-04

No results posted yet for this study

Summary

Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group

Conditions

  • Asthma; Eosinophilic

Interventions

BIOLOGICAL

Dupilumab

600 mg (two 300 mg injections), followed by 300 mg monthly

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05787678 on ClinicalTrials.gov